Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance

被引：0

作者：

Koga, T. ^{[1
]}

Kobayashi, Y. ^{[2
]}

Tomizawa, K. ^{[1
]}

Sesumi, Y. ^{[1
]}

Fujino, T. ^{[1
]}

Nishino, M. ^{[1
]}

Ohara, S. ^{[1
]}

Chiba, M. ^{[1
]}

Shimoji, M. ^{[1
]}

Suda, K. ^{[1
]}

Takemoto, T. ^{[1
]}

Mitsudomi, T. ^{[1
]}

机构：

[1] Kinda Univ, Fac Med, Thorac Surg, Osaka, Japan

[2] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

NSCLC; HER2; Poziotinib;

D O I：

10.1016/j.jtho.2018.08.899

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.13-42

引用

页码：S598 / S599

页数：2

共 50 条

[1] Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Koga, Takamasa
Kobayashi, Yoshihisa
Tomizawa, Kenji
Suda, Kenichi
Kosaka, Takayuki
Sesumi, Yuichi
Fujino, Toshio
Nishino, Masaya
Ohara, Shuta
Chiba, Masato
Shimoji, Masaki
Takemoto, Toshiki
Suzuki, Makoto
Janne, Pasi A.
Mitsudomi, Tetsuya
[J]. LUNG CANCER, 2018, 126 : 72 - 79
[2] Potent in Vitro Activity of Tarloxotinib for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
Koga, T.
Suda, K.
Nishino, M.
Fujino, T.
Ohara, S.
Soh, J.
Vellanki, A.
Tirunagaru, V.
Misudomi, T.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S690 - S691
[3] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
不详
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Identification of Frequent, Activating HER2 Mutations and HER2 Inhibitor Response and Resistance in Canine Lung Cancer
Lorch, G.
Zismann, V.
Perdigones, N.
Contente-Cuomo, T.
Nazareno, A.
Facista, S.
Wong, S.
Liang, W.
Amann, J.
Sinicropi-Yao, S.
Koenig, M.
La Perle, K.
Lalani, A.
Diala, I.
Eli, L.
Whitsett, T.
Trent, J.
Murtaza, M.
Carbone, D.
Hendricks, W.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S832 - S833
[5] HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib
Fan, Ying
Qin, Jing
Han, Na
Lu, Hongyang
[J]. ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (04) : 1582 - 1588
[6] Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Marin, Arnaldo
Al Mamun, Abdullah
Patel, Hima
Akamatsu, Hiroaki
Ye, Dan
Sudhan, Dhivya R.
Eli, Lisa
Marcelain, Katherine
Brown, Benjamin P.
Meiler, Jens
Arteaga, Carlos L.
Hanker, Ariella B.
[J]. CANCER RESEARCH, 2023, 83 (18) : 3145 - 3158
[7] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
Prelaj, A.
Bottiglieri, A.
Galli, E.
Lo Russo, G.
Ferrara, R.
Galli, G.
De Toma, A.
Brambilla, M.
Occhipinti, M.
Manglaviti, S.
Beninato, T.
Zattarin, E.
Apollonio, G.
Ganzinelli, M.
Gallucci, R.
Di Mauro, R. M.
de Braud, F.
Torri, V.
Garassino, M. C. C.
Proto, C.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
[8] Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
Koga, Takamasa
Suda, Kenichi
Nishino, Masaya
Fujino, Toshio
Ohara, Shuta
Hamada, Akira
Soh, Junichi
Tirunagaru, Vijaya
Vellanki, Avanish
Doebele, Robert C.
Mitsudomi, Tetsuya
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (08) : 3659 - +
[9] Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
Wang, Bi-Cheng
Kuang, Bo-Hua
Liu, Xin-Xiu
Lin, Guo-He
[J]. MEDICINE, 2022, 101 (44) : E31337
[10] Secondary C805S Mutation in HER2 Gene Confers Acquired Resistance to HER2 Kinase Inhibitors in HER2 Mutant Lung Cancer
Kosaka, Takayuki
Endoh, Hideki
Repellin, Claire
Tanizaki, Junko
Ercan, Dalia
Capelletti, Marzia
Jaenne, Pasi A.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S296 - S296

← 1 2 3 4 5 →